Clinical Trial Update: Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Halaven (eribulin)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: UNKNOWN